Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis

Company Overview

Santen Pharmaceutical Co., Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist. The company maintains commercial operations across Asia, Europe, North America and emerging markets, supporting the needs of eye care professionals and patients worldwide. Through strategic partnerships and in‐licensing agreements, Santen has expanded its footprint in key regions including China, the United States and the European Union, aligning its commercial network with local regulatory frameworks and medical practices.

Santen invests heavily in research and development to advance innovative treatments and refine existing therapies. Its R&D activities span early‐stage discovery through late‐stage clinical trials, with dedicated centers in Japan, Finland and the United States. The company’s pipeline comprises candidates targeting chronic and acute ophthalmic conditions, backed by collaborations with academic institutions and specialty biotech firms. Santen’s leadership team combines seasoned executives in pharmaceuticals and medical devices with experts in global market strategy, underscoring its commitment to delivering value through science‐driven innovation in eye health.

Key Stats

• Today's Range: $11.77 to $12.15
• 50-Day Range: $11.22 to $13.90
• 52-Week Range: $9.22 to $13.93
• Volume: 743 shs
• Average Volume: 2,510 shs
• Market Capitalization: $3.79 billion
• P/E Ratio: N/A
• Dividend Yield: 1.19%
• Price Target: N/A
• Consensus Rating: Hold

Santen Pharmaceutical Stock Analysis - MarketRank™

Santen Pharmaceutical scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Santen Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Santen Pharmaceutical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 23.68%

Earnings Growth

Earnings for Santen Pharmaceutical are expected to grow by 23.68% in the coming year, from $0.76 to $0.94 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Santen Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Santen Pharmaceutical has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Santen Pharmaceutical has recently increased by 235.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Santen Pharmaceutical pays a meaningful dividend of 1.19%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Santen Pharmaceutical does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Santen Pharmaceutical will have a dividend payout ratio of 14.89% next year. This indicates that Santen Pharmaceutical will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.76

News Sentiment

Santen Pharmaceutical has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Santen Pharmaceutical this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

Santen Pharmaceutical has minimal institutional ownership at this time.

Company Calendar

• Today: 8/09/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SNPHY
• CIK: 1501108
• Web: www.santen.com
• Phone: (167) 664-8621
• Fax: N/A
• Employees: 4,144
• Year Founded: 1890

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 322,290,000
• Free Float: N/A
• Market Cap: $3.79 billion
• Optionable: Not Optionable
• Beta: N/A